Wnt signaling in cardiovascular physiology

Trends in Endocrinology and Metabolism

Volumn 23, Issue 12, 2012, Pages 628-636

  Marinou, K ^a   Christodoulides, C ^b   Antoniades, C ^c   Koutsilieris, M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atherosclerosis; Calcification; Inflammation; Vascular smooth muscle cells; Wnt

Indexed keywords

BETA CATENIN; CADHERIN; FRIZZLED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; WNT PROTEIN;

ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; COMPLEX FORMATION; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; MESENCHYMAL STEM CELL; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; CALCINOSIS; CARDIOMEGALY; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CELL ADHESION; HUMANS; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; SIGNAL TRANSDUCTION; VASCULAR DISEASES; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84869505072     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.06.001     Document Type: Review

References (89)

1. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
2. Liu Y., Shanahan C.M. Signalling pathways and vascular calcification. Front. Biosci. 2011, 16:1302-1314.
3. 2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 2000, 16:279-283.
4. 2+ pathways. Oncogene 1999, 18:7860-7872.
5. Dejana E. The role of wnt signaling in physiological and pathological angiogenesis. Circ. Res. 2010, 107:943-952.
6. Kim J., et al. Wnt5a induces endothelial inflammation via beta-catenin-independent signaling. J. Immunol. 2010, 185:1274-1282.
7. van Gijn M.E., et al. The wnt-frizzled cascade in cardiovascular disease. Cardiovasc. Res. 2002, 55:16-24.
8. Tsaousi A., et al. The Wnt pathways in vascular disease: lessons from vascular development. Curr. Opin. Lipidol. 2011, 22:350-357.
9. Luo J., et al. Wnt signaling and human diseases: what are the therapeutic implications?. Lab. Invest. 2007, 87:97-103.
10. Rao T.P., Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ. Res. 2010, 106:1798-1806.
11. Habas R., Dawid I.B. Dishevelled and Wnt signaling: is the nucleus the final frontier?. J. Biol. 2005, 4:2.
12. Schulte G., Bryja V. The Frizzled family of unconventional G-protein-coupled receptors. Trends Pharmacol. Sci. 2007, 28:518-525.
13. Xu Q., et al. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell 2004, 116:883-895.
14. Caneparo L., et al. Dickkopf-1 regulates gastrulation movements by coordinated modulation of Wnt/beta catenin and Wnt/PCP activities, through interaction with the Dally-like homolog Knypek. Genes Dev. 2007, 21:465-480.
15. Kestler H.A., Kuhl M. Generating a Wnt switch: it's all about the right dosage. J. Cell Biol. 2011, 193:431-433.
16. Maye P., et al. Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway. J. Biol. Chem. 2004, 279:24659-24665.
17. 2+ pathway to antagonize Wnt/beta-catenin signaling. Mol. Cell. Biol. 2003, 23:131-139.
18. Topol L., et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J. Cell Biol. 2003, 162:899-908.
19. Mikels A.J., Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006, 4:e115.
20. Huelsken J., Behrens J. The Wnt signalling pathway. J. Cell Sci. 2002, 115:3977-3978.
21. Antoniades C., et al. Targeting redox signaling in the vascular wall: from basic science to clinical practice. Curr. Pharm. Des. 2009, 15:329-342.
22. Pober J.S., Sessa W.C. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 2007, 7:803-815.
23. Christman M.A., et al. Wnt5a is expressed in murine and human atherosclerotic lesions. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H2864-H2870.
24. Blumenthal A., et al. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006, 108:965-973.
25. Ueland T., et al. Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1228-1234.
26. Kim K.I., et al. A novel biomarker of coronary atherosclerosis: serum DKK1 concentration correlates with coronary artery calcification and atherosclerotic plaques. J. Korean Med. Sci. 2011, 26:1178-1184.
27. Seifert-Held T., et al. Circulating Dickkopf-1 in acute ischemic stroke and clinically stable cerebrovascular disease. Atherosclerosis 2011, 218:233-237.
28. Shao J.S., et al. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann. N. Y. Acad. Sci. 2007, 1117:40-50.
29. -/- mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2589-2596.
30. Bostrom K., et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J. Clin. Invest. 1993, 91:1800-1809.
31. Shao J.S., et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J. Clin. Invest. 2005, 115:1210-1220.
32. Towler D.A., et al. Osteogenic regulation of vascular calcification. Ann. N. Y. Acad. Sci. 2006, 1068:327-333.
33. Bostrom K.I., et al. The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ. Res. 2011, 109:564-577.
34. Abedin M., et al. Mesenchymal stem cells and the artery wall. Circ. Res. 2004, 95:671-676.
35. Abedin M., et al. Vascular calcification: mechanisms and clinical ramifications. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1161-1170.
36. Romanov Y.A., et al. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 2003, 21:105-110.
37. Wilkinson F.L., et al. Contribution of VCAF-positive cells to neovascularization and calcification in atherosclerotic plaque development. J. Pathol. 2007, 211:362-369.
38. Kirton J.P., et al. Wnt/beta-catenin signaling stimulates chondrogenic and inhibits adipogenic differentiation of pericytes: potential relevance to vascular disease?. Circ. Res. 2007, 101:581-589.
39. Hunt J.L., et al. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002, 33:1214-1219.
40. Qiao J.H., et al. Cartilaginous metaplasia in calcified diabetic peripheral vascular disease: morphologic evidence of enchondral ossification. Hum. Pathol. 2003, 34:402-407.
41. Stehbens W.E. Chronic vascular changes in the walls of experimental berry aneurysms of the aortic bifurcation in rabbits. Stroke 1981, 12:643-647.
42. Ohtsuka S., et al. Chronically decreased aortic distensibility causes deterioration of coronary perfusion during increased left ventricular contraction. J. Am. Coll. Cardiol. 1994, 24:1406-1414.
43. Lee D.K., et al. Activation of the canonical Wnt/beta-catenin pathway enhances monocyte adhesion to endothelial cells. Biochem. Biophys. Res. Commun. 2006, 347:109-116.
44. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 1994, 344:793-795.
45. Bienz M. Beta-catenin: a pivot between cell adhesion and Wnt signalling. Curr. Biol. 2005, 15:R64-R67.
46. Tickenbrock L., et al. Wnt signaling regulates transendothelial migration of monocytes. J. Leukoc. Biol. 2006, 79:1306-1313.
47. Wang X., et al. A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. Circ. Res. 2002, 90:340-347.
48. Slater S.C., et al. R-cadherin:beta-catenin complex and its association with vascular smooth muscle cell proliferation. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1204-1210.
49. Tsaousi A., et al. Wnt4/β-catenin signaling induces VSMC proliferation and is associated with intimal thickening. Circ. Res. 2011, 108:427-436.
50. Dwivedi A., et al. MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc. Res. 2009, 81:178-186.
51. George S.J., Beeching C.A. Cadherin:catenin complex: a novel regulator of vascular smooth muscle cell behaviour. Atherosclerosis 2006, 188:1-11.
52. Quasnichka H., et al. Regulation of smooth muscle cell proliferation by beta-catenin/T-cell factor signaling involves modulation of cyclin D1 and p21 expression. Circ. Res. 2006, 99:1329-1337.
53. Laeremans H., et al. Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation 2011, 124:1626-1635.
54. von Marschall Z., Fisher L.W. Secreted Frizzled-related protein-2 (sFRP2) augments canonical Wnt3a-induced signaling. Biochem. Biophys. Res. Commun. 2010, 400:299-304.
55. Zhang Z., et al. Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. J. Mol. Cell. Cardiol. 2009, 46:370-377.
56. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349:1436-1442.
57. Hsieh J.C., et al. Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell 2003, 112:355-367.
58. Liu W., et al. Mutation in EGFP domain of LDL receptor-related protein 6 impairs cellular LDL clearance. Circ. Res. 2008, 103:1280-1288.
59. Mani A., et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007, 315:1278-1282.
60. Sarzani R., et al. Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant. Nutr. Metab. Cardiovasc. Dis. 2011, 21:150-156.
61. Grant S.F., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 2006, 38:320-323.
62. Rulifson I.C., et al. Wnt signaling regulates pancreatic beta cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:6247-6252.
63. Manolagas S.C., Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol. Endocrinol. 2007, 21:2605-2614.
64. Yi F., et al. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 2008, 149:2341-2351.
65. Kanazawa A., et al. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am. J. Hum. Genet. 2004, 75:832-843.
66. Gong Y., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
67. Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia 2008, 51:1771-1780.
68. Laudes M. Role of WNT signaling in the determination of human mesenchymal stem cells into preadipocytes. J. Mol. Endocrinol. 2011, 46:65-72.
69. Christodoulides C., et al. Adipogenesis and WNT signalling. Trends Endocrinol. Metab. 2009, 20:16-24.
70. Ross S.E., et al. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
71. Bluher M. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diab. 2009, 117:241-250.
72. Gustafson B., et al. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2276-2283.
73. Hajer G.R., et al. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 2008, 29:2959-2971.
74. Samocha-Bonet D., et al. Insulin-sensitive obesity in humans - a 'favorable fat' phenotype?. Trends Endocrinol. Metab. 2012, 23:116-124.
75. Xu H., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
76. Ouchi N., et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010, 329:454-457.
77. Oh D.Y., Olefsky J.M. Medicine. Wnt fans the flames in obesity. Science 2010, 329:397-398.
78. Gessert S., Kuhl M. The multiple phases and faces of wnt signaling during cardiac differentiation and development. Circ. Res. 2010, 107:186-199.
79. Korol O., et al. A novel activity of the Dickkopf-1 amino terminal domain promotes axial and heart development independently of canonical Wnt inhibition. Dev. Biol. 2008, 324:131-138.
80. Wehrli M., et al. Arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature 2000, 407:527-530.
81. Bienz M., Clevers H. Armadillo/beta-catenin signals in the nucleus - proof beyond a reasonable doubt?. Nat. Cell Biol. 2003, 5:179-182.
82. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
83. Pronobis M.I., Peifer M. Wnt signaling: the many interfaces of beta-catenin. Curr. Biol. 2012, 22:R137-R139.
84. 2+/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J. Biol. Chem. 2000, 275:12701-12711.
85. Wang H.Y., Malbon C.C. Wnt-frizzled signaling to G-protein-coupled effectors. Cell. Mol. Life Sci. 2004, 61:69-75.
86. Johnson M.L., Rajamannan N. Diseases of Wnt signaling. Rev. Endocr. Metab. Disord. 2006, 7:41-49.
87. Wang Y. Wnt/Planar cell polarity signaling: a new paradigm for cancer therapy. Mol. Cancer Ther. 2009, 8:2103-2109.
88. Mlodzik M. Planar cell polarization: do the same mechanisms regulate Drosophila tissue polarity and vertebrate gastrulation?. Trends Genet. 2002, 18:564-571.
89. Capelluto D.G., et al. The DIX domain targets dishevelled to actin stress fibres and vesicular membranes. Nature 2002, 419:726-729.